The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque

RationaleThe current standards of care for Alzheimer’s disease, acetylcholinesterase inhibitors, have limited efficacy due to a host of mechanism-related side effects arising from indiscriminate activation of muscarinic and nicotinic receptors. The M1 muscarinic receptor is predominantly expressed in the brain in regions involved in cognition, and therefore selective activation of the M1 receptor would be expected to boost cognitive performance with reduced risk of peripheral side effects.ObjectivesHere we investigated whether the selective M1 muscarinic receptor positive allosteric modulator, PQCA, improves cognitive performance and cerebral blood flow.ResultsPQCA attenuated a scopolamine-induced deficit in novel object recognition in rat, self-ordered spatial search in cynomolgus macaque, and the object retrieval detour task in rhesus macaque. Beneficial effects in each of these assays and species were observed at similar plasma drug concentrations. Furthermore, at similar drug concentrations that were effective in the behavioral studies, PQCA increased blood flow in the frontal cortex of mice, providing a translational biomarker that could be used to guide dose selection for clinical studies.ConclusionsThese findings provide a framework for appropriately testing an M1 selective compound in patients with Alzheimer’s disease.

[1]  Annalena Venneri,et al.  Imaging treatment effects in Alzheimer's disease. , 2007, Magnetic resonance imaging.

[2]  S. Jadhav,et al.  Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. , 2010, ACS chemical neuroscience.

[3]  Craig W. Lindsley,et al.  Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation , 2009, Proceedings of the National Academy of Sciences.

[4]  O. Scremin,et al.  Cholinergic Control of Blood Flow in the Cerebral Cortex of the Rat , 1973, Stroke.

[5]  R. Eglen.  Muscarinic receptor subtype pharmacology and physiology. , 2005, Progress in medicinal chemistry.

[6]  J. Wess,et al.  Hyperactivity and Intact Hippocampus-Dependent Learning in Mice Lacking the M1 Muscarinic Acetylcholine Receptor , 2001, The Journal of Neuroscience.

[7]  M. Seager,et al.  N-heterocyclic derived M1 positive allosteric modulators. , 2010, Bioorganic & medicinal chemistry letters.

[8]  Xiao-Hua Cao,et al.  A novel derivative of xanomeline improved memory function in aged mice , 2008, Neuroscience bulletin.

[9]  L. Squire,et al.  Successful performance by monkeys with lesions of the hippocampal formation on AB and object retrieval, two tasks that mark developmental changes in human infants. , 1989, Behavioral neuroscience.

[10]  Wen J. Li,et al.  Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment , 2012, NeuroImage.

[11]  A C Roberts,et al.  Primate analogue of the Wisconsin Card Sorting Test: effects of excitotoxic lesions of the prefrontal cortex in the marmoset. , 1996, Behavioral neuroscience.

[12]  W W Offen,et al.  The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. , 1997, Alzheimer disease and associated disorders.

[13]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[14]  C. Lindsley,et al.  Discovery and development of a second highly selective M1 Positive Allosteric Modulator (PAM) , 2010 .

[15]  J. Buccafusco,et al.  The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist. , 2000, The Journal of pharmacology and experimental therapeutics.

[16]  E. Giacobini,et al.  Heptyl‐physostigmine enhances basal forebrain control of cortical cerebral blood flow , 1992, Journal of neuroscience research.

[17]  David Fernández de Sevilla,et al.  The Muscarinic Long-Term Enhancement of NMDA and AMPA Receptor-Mediated Transmission at Schaffer Collateral Synapses Develop through Different Intracellular Mechanisms , 2010, The Journal of Neuroscience.

[18]  D. A. Brown,et al.  POSTSYNAPTIC ACTIONS OF ACETYLCHOLINE - THE COUPLING OF MUSCARINIC RECEPTOR SUBTYPES TO NEURONAL ION CHANNELS , 1993 .

[19]  D. Price,et al.  Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[20]  S. Jadhav,et al.  Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. , 2010, ACS chemical neuroscience.

[21]  A. Christopoulos,et al.  Cellular Signaling Mechanisms for Muscarinic Acetylcholine Receptors , 2003 .

[22]  Facilitation of Long-Term Potentiation by Muscarinic M1 Receptors Is Mediated by Inhibition of SK Channels , 2010, Neuron.

[23]  S. Yamada,et al.  Functional analysis of muscarinic acetylcholine receptors using knockout mice. , 2004, Life sciences.

[24]  Adrian M. Owen,et al.  Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man , 1995, Neuropsychologia.

[25]  F. Kagitani,et al.  Control of cerebral cortical blood flow by stimulation of basal forebrain cholinergic areas in mice , 2011, The Journal of Physiological Sciences.

[26]  A. C. Roberts,et al.  Perseveration and Strategy in a Novel Spatial Self-Ordered Sequencing Task for Nonhuman Primates: Effects of Excitotoxic Lesions and Dopamine Depletions of the Prefrontal Cortex , 1998, Journal of Cognitive Neuroscience.

[27]  D. Peters,et al.  Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. , 2006, CNS drug reviews.

[28]  B. Sabatini,et al.  M1 Muscarinic Receptors Boost Synaptic Potentials and Calcium Influx in Dendritic Spines by Inhibiting Postsynaptic SK Channels , 2010, Neuron.

[29]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[30]  A. Levey,et al.  Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Piché,et al.  Modulation of somatosensory‐evoked cortical blood flow changes by GABAergic inhibition of the nucleus basalis of Meynert in urethane‐anaesthetized rats , 2010, The Journal of physiology.

[32]  C. Felder.  Muscarinic acetylcholine receptors: signal transduction through multiple effectors , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  D. Sheffler,et al.  Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe. , 2011, Bioorganic & medicinal chemistry letters.

[34]  Malcolm W. Brown,et al.  Different Contributions of the Hippocampus and Perirhinal Cortex to Recognition Memory , 1999, The Journal of Neuroscience.

[35]  Y. Sato,et al.  Cerebral cortical vasodilatation in response to stimulation of cholinergic fibres originating in the nucleus basalis of Meynert. , 1990, Journal of the autonomic nervous system.

[36]  B. Vellas,et al.  Managing Cognitive Dysfunction through the Continuum of Alzheimer’s Disease , 2011, CNS Drugs.

[37]  M. Quirk,et al.  A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning , 2009, The Journal of Neuroscience.

[38]  A Olivier,et al.  Functional Acetylcholine Muscarinic Receptor Subtypes in Human Brain Microcirculation: Identification and Cellular Localization , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  Scott Baker,et al.  Xanomeline Modulation of the Blood Oxygenation Level-Dependent Signal in Awake Rats: Development of Pharmacological Magnetic Resonance Imaging as a Translatable Pharmacodynamic Biomarker for Central Activity and Dose Selection , 2012, Journal of Pharmacology and Experimental Therapeutics.

[40]  F. Mascagni,et al.  Neuronal localization of m1 muscarinic receptor immunoreactivity in the rat basolateral amygdala , 2010, Brain Structure and Function.

[41]  M. Seager,et al.  Pyridine containing M(1) positive allosteric modulators with reduced plasma protein binding. , 2010, Bioorganic & medicinal chemistry letters.

[42]  S. Hitchcock,et al.  Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist , 2011, Journal of Pharmacology and Experimental Therapeutics.

[43]  T. Manabe,et al.  Modulation of Synaptic Plasticity by Physiological Activation of M1 Muscarinic Acetylcholine Receptors in the Mouse Hippocampus , 2005, The Journal of Neuroscience.

[44]  E. Halgren,et al.  Divided attention-enhancing effects of AF102B and THA in aging monkeys , 1999, Psychopharmacology.

[45]  J. Wess,et al.  Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. , 2004, Annual review of pharmacology and toxicology.

[46]  Alcino J. Silva,et al.  Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice , 2003, Nature Neuroscience.

[47]  J. Connor,et al.  Specific involvement of Ca(2+)-calmodulin kinase II in cholinergic modulation of neuronal responsiveness. , 1992, Journal of neurophysiology.

[48]  A. Levey,et al.  Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. , 1993, Life sciences.

[49]  B. Pitt.  Psychopharmacology , 1968, Mental Health.

[50]  A. Ashkenazi,et al.  Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes , 1988, Nature.

[51]  Xiaohua Cao,et al.  A novel derivative of xanomeline improves fear cognition in aged mice , 2010, Neuroscience Letters.

[52]  H. Tecle,et al.  Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. , 1999, The Journal of pharmacology and experimental therapeutics.

[53]  Tim Lock,et al.  Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. , 2009, European journal of pharmacology.

[54]  S. Kelly,et al.  Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer’s Disease: Systematic Review of the ‘Real-World’ Evidence , 2009, Dementia and Geriatric Cognitive Disorders.

[55]  M. Seager,et al.  Quinolizidinone carboxylic acid selective M1 allosteric modulators: SAR in the piperidine series. , 2011, Bioorganic & medicinal chemistry letters.

[56]  A. Deutch,et al.  Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats , 2008, The Journal of Neuroscience.

[57]  A. Levey,et al.  Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. , 2004, Progress in brain research.

[58]  D. Mumby,et al.  Rhinal cortex lesions and object recognition in rats. , 1994, Behavioral neuroscience.

[59]  Kimihiko Abe,et al.  Regional Cerebral Blood Flow Patterns and Response to Donepezil Treatment in Patients with Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[60]  K. Geering,et al.  Adrenergic, dopaminergic, and muscarinic receptor stimulation leads to PKA phosphorylation of Na-K-ATPase. , 1996, The American journal of physiology.

[61]  William J Ray,et al.  Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold. , 2011, Journal of medicinal chemistry.

[62]  J. Wess,et al.  Muscarinic Induction of Hippocampal Gamma Oscillations Requires Coupling of the M1 Receptor to Two Mixed Cation Currents , 2002, Neuron.

[63]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[64]  T. Bonner,et al.  The striatum and cerebral cortex express different muscarinic receptor mRNAs , 1988, FEBS letters.

[65]  E. Halgren,et al.  Effects of AF102B and Tacrine on delated match-to-sample in monkeys , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[66]  K. Mcfarland,et al.  AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model , 2010, Neuropharmacology.

[67]  M. Seager,et al.  Fused heterocyclic M1 positive allosteric modulators. , 2011, Bioorganic & medicinal chemistry letters.

[68]  B. Bloch,et al.  Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[69]  Eric Halgren,et al.  Reduction in distractibility with AF102B and THA in the macaque , 2003, Pharmacology Biochemistry and Behavior.

[70]  S. Stahl.  Cholinesterase inhibitors for Alzheimer's disease. , 1998, Hospital practice.

[71]  W W Offen,et al.  Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. , 1997, Archives of neurology.